Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to give voluntary informed consent and understand the study and are willing to follow and complete all the test procedures.~2. Aged ≥ 18 years.~3. Life expectancy ≥ 3 months.~4. ECOG performance status ≤ 1.~5. Histologically/cytologically confirmed, locally advanced unresectable or metastatic solid tumors that are refractory to standard therapy, or for whom no standard therapy exists.~6. Has measurable disease per RECIST v1.1. that was not in a prior radiation or other locally treated area, unless imaging-based progression has been clearly documented following radiation or other local therapy.~Exclusion Criteria:~1. Females who are pregnant or nursing.~2. Receiving concurrent anticancer therapy or investigational therapy (including chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, targeted therapy, biologic therapy).~3. Has remaining AEs \> Grade 1 from prior antitumor treatment as per CTCAE v5.0, with the exception of alopecia.~4. Participants with primacy central nervous system (CNS) malignancy, symptomatic CNS metastases, meningeal metastases or leptomeningeal disease are not allowed. Note: Participants with asymptomatic CNS metastases are eligible if clinically controlled, which is defined as 1) ≥ 4 weeks of stable neurologic function following CNS-directed therapy prior to Screening, 2) no evidence of CNS disease progression as determined by radiographic imaging ≥ 4 weeks prior to Screening, 3) ≥ 2 weeks from discontinuation of anti-seizure and steroid therapies (receiving prednisone ≤ 10mg or equivalent steroid therapies is allowed) prior to Screening.~5. Had major surgery within 28-days of the Screening Visit. Note: Participants who have undergone a non-major surgical procedure ≥ 28 days prior to Screening must have recovered adequately from the toxicity and/or complications from the intervention before administration of the first dose of study drugs.~6. History of tissue or organ transplantation.~7. History of severe infection deemed clinically significant by the PI or designee within 4 weeks or signs and symptoms of any active infection within 2 weeks prior to the first dose of study drugs.~8. History of human immunodeficiency virus (HIV) infection or history of autoimmune diseases.~9. Active hepatitis B or C. Note: Hepatitis B virus (HBV) carriers without active disease (HBV DNA titer \< 1000 copies/mL or 200 IU/mL) or cured Hepatitis C (negative HCV RNA test) may be enrolled.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 mg of BAT6021 (Type: EXPERIMENTAL): BAT6021 100mg/vial，10mg Ⅳ infusions
- 30 mg of BAT6021 (Type: EXPERIMENTAL): BAT6021 100mg/vial，30mg Ⅳ infusions
- 100 mg of BAT6021 (Type: EXPERIMENTAL): BAT6021 100mg/vial，100mg Ⅳ infusions
- 300 mg of BAT6021 (Type: EXPERIMENTAL): BAT6021 100mg/vial，300mg Ⅳ infusions
- 600 mg of BAT6021 (Type: EXPERIMENTAL): BAT6021 100mg/vial，600mg Ⅳ infusions
- 900 mg of BAT6021 (Type: EXPERIMENTAL): BAT6021 100mg/vial，900mg Ⅳ infusions
- 100mg BAT6021+300mg BAT1308 (Type: EXPERIMENTAL): BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 100mg+BAT1308 300mg Ⅳ infusions
- 300mg BAT6021+300mg BAT1308 (Type: EXPERIMENTAL): BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 300mg+BAT1308 300mg Ⅳ infusions
- 600mg BAT6021+300mg BAT1308 (Type: EXPERIMENTAL): BAT6021 100mg/vial，BAT1308 100mg/vial ; BAT6021 600mg+BAT1308 300mg Ⅳ infusions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy